This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Investors are optimistic about Align Technology's (ALGN) better-than-expected results and growing uptake of iTero scanners in the third quarter of fiscal 2021.
Medtronic (MDT) Gets Health Canada License for Hugo RAS System
by Zacks Equity Research
The receipt of the Health Canada license for Medtronic's (MDT) Hugo RAS System is likely to enhance accessibility to robotic-assisted surgery in Canada.
Here's Why You Should Invest in AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.
Integer Holdings (ITGR) Buys Oscor, Boosts Global Footprint
by Zacks Equity Research
Integer Holdings' (ITGR) acquisition of Oscor is likely to bolster its already solid global presence.
QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay
by Zacks Equity Research
QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Avanos Medical's (AVNS) App to Support Pain Management Process
by Zacks Equity Research
Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.
Change Healthcare (CHNG) Cloud-Native PACS Now in Clinical Use
by Zacks Equity Research
The clinical use of Change Healthcare's (CHNG) cloud-native Stratus Imaging PACS is likely to enhance radiologists' productivity.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.
Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection
by Zacks Equity Research
Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.
Henry Schein (HSIC) Introduces Treatment Planning Software
by Zacks Equity Research
The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.
McKesson (MCK) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR.
Walgreens (WBA) Buys Remaining Stake in German Wholesale Business
by Zacks Equity Research
Walgreens' (WBA) recent acquisition of the remaining ownership stake helps the company to further solidify its position as a leading pharmaceutical wholesaler in Germany.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.
Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks
by Urmimala Biswas
According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical and Cardinal Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical and Cardinal Health
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Promising Stocks From the Buoyant Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
McKesson (MCK) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.
PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis
by Zacks Equity Research
PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.